ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: Absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Cleton Jansen, Anne Marie ^a   van Eijk, Ronald ^a   Lombaerts, Marcel ^a   Schmidt, Marjanka K ^b   Van't Veer, Laura J ^b   Philippo, Katja ^a   Zimmerman, Rhyenne M E ^a   Peterse, Johannes L ^b   Smit, Vincent T B H M ^a   van Wezel, Tom ^a   Cornelisse, Cees J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AT BINDING TRANSCRIPTION FACTOR 1; COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR; ATBF1 PROTEIN, HUMAN; DNA; HOMEODOMAIN PROTEIN; NQO1 PROTEIN, HUMAN; RNA;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INVASION; CARCINOGENESIS; CHROMOSOME 16Q; CONTROLLED STUDY; DETOXIFICATION; DNA MICROARRAY; DNA SEQUENCE; ENZYME ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; CHROMOSOME 16; COMPARATIVE STUDY; DOWN REGULATION; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 16; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NAD(P)H DEHYDROGENASE (QUINONE); OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, GENETIC; RNA, MESSENGER; RNA, NEOPLASM;

EID: 43949113698     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-105     Document Type: Article

References (44)

1. Miller BJ Wang D Krahe R Wright FA Pooled analysis of loss of heterozygosity in breast cancer: A genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions Am J Hum Genet 2003, 73:748-767. 1180599 13680524 10.1086/378522
2. Cleton-Jansen AM Callen DF Seshadri R Goldup S McCallum B Crawford J Powell JA Settasatian C van Beerendonk H Moerland EW Smit VT Harris WH Millis R Morgan NV Barnes D Mathew CG Cornelisse CJ Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions Cancer Res 2001, 61:1171-1177. 11221848
3. Berx G Cleton-Jansen AM Nollet F De Leeuw WJF Van de Vijver MJ Cornelisse C Van Roy F E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers EMBO Journal 1995, 14:6107-6115. 394735 8557030
4. Aulmann S Blaker H Penzel R Rieker RJ Otto HF Sinn HP CTCF gene mutations in invasive ductal breast cancer Breast Cancer Res Treat 2003, 80:347-352. 10.1023/A:1024930404629 14503807
5. Filippova GN Qi CF Ulmer JE Moore JM Ward MD Hu YJ Loukinov DI Pugacheva EM Klenova EM Grundy PE Feinberg AP Cleton-Jansen AM Moerland EW Cornelisse CJ Suzuki H Komiya A Lindblom A Dorion-Bonnet F Neiman PE Morse HC III Collins SJ Lobanenkov VV Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity Cancer Res 2002, 62:48-52 11782357
6. Kochetkova M McKenzie OL Bais AJ Martin JM Secker GA Seshadri R Powell JA Hinze SJ Gardner AE Spendlove HE O'Callaghan NJ Cleton-Jansen AM Cornelisse C Whitmore SA Crawford J Kremmidiotis G Sutherland GR Callen DF CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3 Cancer Res 2002, 62:4599-4604. 12183414
7. Kumar R Neilsen PM Crawford J McKirdy R Lee J Powell JA Saif Z Martin JM Lombaerts M Cornelisse CJ Cleton-Jansen AM Callen DF FBXO31 Is the Chromosome 16q24.3 Senescence Gene, a Candidate Breast Tumor Suppressor, and a Component of an SCF Complex Cancer Res 2005, 65:11304-11313. 10.1158/0008-5472.CAN-05-0936 16357137
8. Cleton-Jansen AM E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: Different genetic pathways in ductal and lobular breast cancer? Breast Cancer Research 2001, 4:5-8. 138715 11879552 10.1186/bcr416
9. Sun X Frierson HF Chen C Li C Ran Q Otto KB Cantarel BL Vessella RL Gao AC Petros J Miura Y Simons JW Dong JT Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer Nat Genet 2005, 37:407-412. 10.1038/ng1528 15750593
10. Morinaga T Yasuda H Hashimoto T Higashio K Tamaoki T A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers Mol Cell Biol 1991, 11:6041-6049. 361769 1719379
11. Kaspar P Dvorakova M Kralova J Pajer P Kozmik Z Dvorak M Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein J Biol Chem 1999, 274:14422-14428. 10.1074/jbc.274.20.14422 10318867
12. Miura Y Kataoka H Joh T Tada T Asai K Nakanishi M Okada N Okada H Susceptibility to killer T cells of gastric cancer cells enhanced by Mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/ Cip1) promoter Microbiol Immunol 2004, 48:137-145. 14978340
13. Asher G Lotem J Cohen B Sachs L Shaul Y Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1 Proc Natl Acad Sci U S A 2001, 98:1188-1193. 14730 11158615 10.1073/pnas.021558898
14. Ross D Siegel D NAD(P)H:qUinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics Methods Enzymol 2004, 382:115-144. 15047100
15. de Bock GH Schutte M Krol-Warmerdam EM Seynaeve C Blom J Brekelmans CT Meijers-Heijboer H van Asperen CJ Cornelisse CJ Devilee P Tollenaar RA Klijn JG Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant J Med Genet 2004, 41:731-735. 1735606 15466005 10.1136/jmg.2004.019737
16. http://www.imagenes-bio.de/
17. http://www.Kazusa.org
18. Lombaerts M van Wezel T Philippo K Dierssen JW Zimmerman RM Oosting J van Eijk R Eilers PH van de WB Cornelisse CJ Cleton-Jansen AM E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines Br J Cancer 2006, 94:661-671. 16495925
19. Ross DT Scherf U Eisen MB Perou CM Rees C Spellman P Iyer V Jeffrey SS van de RM Waltham M Pergamenschikov A Lee JC Lashkari D Shalon D Myers TG Weinstein JN Botstein D Brown PO Systematic variation in gene expression patterns in human cancer cell lines Nat Genet 2000, 24:227-235. 10.1038/73432 10700174
20. http://www.R-project.org/.
21. http://www.bioconductor.org/
22. van Wezel T Lombaerts M van Roon EH Philippo K Baelde HJ Szuhai K Cornelisse CJ Cleton-Jansen AM Expression analysis of candidate breast tumour suppressor genes on chromosome 16q Breast Cancer Res 2005, 7:R998-R1004. 1410740 16280054 10.1186/bcr1337
23. Vandesompele J De Preter K Pattyn F Poppe B Van Roy N De Paepe A Speleman F Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 2002, 3:RESEARCH0034. 126239 12184808 10.1186/gb-2002-3-7-research0034
24. Schmidt MK Tollenaar RA de Kemp SR Broeks A Cornelisse CJ Smit VT Peterse JL van Leeuwen FE Van't Veer LJ Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation J Clin Oncol 2007, 25:64-69. 10.1200/JCO.2006.06.3024 17132695
25. Zappa F Ward T Pedrinis E Butler J McGown A NAD(P)H: Quinone oxidoreductase 1 expression in kidney podocytes J Histochem Cytochem 2003, 51:297-302. 12588957
26. http://www-onderzoek.lumc.nl/Pathology/BreastCancer/
27. Talalay P Fahey JW Holtzclaw WD Prestera T Zhang Y Chemoprotection against cancer by phase 2 enzyme induction Toxicol Lett 1995, 82-83:173-179. 10.1016/0378-4274(95)03553-2 8597048
28. Siegel D Anwar A Winski SL Kepa JK Zolman KL Ross D Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:qUinone oxidoreductase 1 Mol Pharmacol 2001, 59:263-268. 11160862
29. http://www.ensembl.org/
30. Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma Proc Natl Acad Sci U S A 1971, 68:820-823. 389051 5279523 10.1073/ pnas.68.4.820
31. Anwar A Dehn D Siegel D Kepa JK Tang LJ Pietenpol JA Ross D Interaction of human NAD(P)H:qUinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems J Biol Chem 2003, 278:10368-10373. 10.1074/jbc.M211981200 12529318
32. Siegelmann-Danieli N Buetow KH Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:qUinone oxidoreductase 1 detoxification genes in breast cancer development Oncology 2002, 62:39-45. 10.1159/000048245 11810042
33. Traver RD Siegel D Beall HD Phillips RM Gibson NW Franklin WA Ross D Characterization of a polymorphism in NAD(P)H: Quinone oxidoreductase (DT-diaphorase) Br J Cancer 1997, 75:69-75. 9000600
34. Goode EL Dunning AM Kuschel B Healey CS Day NE Ponder BA Easton DF Pharoah PP Effect of germ-line genetic variation on breast cancer survival in a population-based study Cancer Res 2002, 62:3052-3057. 12036913
35. Cleton-Jansen AM Buerger H Haar NN Philippo K Van de Vijver MJ Boecker W Smit VT Cornelisse CJ Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer Genes Chromosomes Cancer 2004, 41:109-116. 10.1002/gcc.20070 15287023
36. Kataoka H Miura Y Joh T Seno K Tada T Tamaoki T Nakabayashi H Kawaguchi M Asai K Kato T Itoh M Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1 Oncogene 2001, 20:869-873. 10.1038/ sj.onc.1204160 11314020
37. Zhang Z Yamashita H Toyama T Sugiura H Ando Y Mita K Hamaguchi M Kawaguchi M Miura Y Iwase H ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer Clin Cancer Res 2005, 11:193-198. 15671546
38. Smith P McGuffog L Easton DF Mann GJ Pupo GM Newman B Chenevix-Trench G Szabo C Southey M Renard H Odefrey F Lynch H Stoppa-Lyonnet D Couch F Hopper JL Giles GG McCredie MR Buys S Andrulis I Senie R Goldgar DE Oldenburg R Kroeze-Jansema K Kraan J Meijers-Heijboer H Klijn JG van Asperen C van L I Vasen HF Cornelisse CJ Devilee P Baskcomb L Seal S Barfoot R Mangion J Hall A Edkins S Rapley E Wooster R Chang-Claude J Eccles D Evans DG Futreal PA Nathanson KL Weber BL Rahman N Stratton MR A genome wide linkage search for breast cancer susceptibility genes Genes Chromosomes Cancer 2006, 45:646-655. 10.1002/gcc.20354 16575876
39. Xu J Sauvageot J Ewing CM Sun J Liu W Isaacs SD Wiley KE Diaz L Zheng SL Walsh PC Isaacs WB Germline ATBF1 mutations and prostate cancer risk Prostate 2006, 66:1082-1085. 10.1002/pros.20430 16637072
40. Pearson CE Nichol EK Cleary JD Repeat instability: Mechanisms of dynamic mutations Nat Rev Genet 2005, 6:729-742. 10.1038/nrg1689 16205713
41. Sun X Zhou Y Otto KB Wang M Chen C Zhou W Subramanian K Vertino PM Dong JT Infrequent mutation of ATBF1 in human breast cancer J Cancer Res Clin Oncol 2007, 133:103-105. 10.1007/s00432-006-0148-y 16932943
42. Imreh S Klein G Zabarovsky ER Search for unknown tumor-antagonizing genes Genes Chromosomes Cancer 2003, 38:307-321. 10.1002/gcc.10271 14566849
43. Devilee P Cleton-Jansen AM Cornelisse CJ Ever since Knudson Trends Genet 2001, 17:569-573. 10.1016/S0168-9525(01)02416-7 11585662
44. Santarosa M Ashworth A Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way Biochim Biophys Acta 2004, 1654:105-122. 15172699